Exploring the options to integrate environmental considerations earlier within drug development.
We will explore the options to incorporate environment considerations earlier in the drug development process to steer development of medicines in a greener direction. PREMIER will develop decision trees for grouping, prioritisation, assessment and targeted testing of existing medicines and support the implementation of these trees in regulatory practice, potentially saving the pharmaceutical industry and the society at large significant amount of resources without compromising environmental protection.
Reassuring patients that medicines are also increasingly safe for the environment by exploring feasible options for design of greener drugs.
The PREMIER project will help to ensure the environmental safety of human medicinal products such that both (i) environmental concerns do not become a barrier to patient access to medicines, and (ii) the intended use of medicines does not pose an unacceptable risk to the environment.
FOR OTHER INDUSTRIES
The tools developed in PREMIER have the potencial to advance the protection of the environment, beyond pharma.
The knowledge and tools generated by PREMIER could also be applied in the assessment of chemical risks across other sectors (e.g., pesticide regulation, food safety), thus amplifying its positive impact on the environment.
Building scientific knowledge.
The evidence-based information system and tools generated by PREMIER will give regulators and the scientific community access to valuable knowledge that can be used to advance on greener medicines.
Supporting the development of a new European standard for environmental protection.
By facilitating access to data and tools to regulators, environmental organisations and policy makers, a new standard for environmental protection across Europe can be adopted. This will strengthen the competitiveness of the European pharmaceutical industry and will promote the industrial leadership of the European Union.
“PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 875508. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA”.